The Alzheimer’s Association leads the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Our vision
is a world without Alzheimer’s and all other dementia.

Join our cause
Learn how you can get involved.
We have entered a new era in the fight against Alzheimer’s and all other dementia, with U.S. Food and Drug Administration-approved treatments available for people living with early Alzheimer’s. By slowing progression of the disease in its early stages, these treatments would allow individuals who are able to access them more time to participate fully in daily life, help make important decisions about their care and live independently. In addition, we know from many other diseases that once the first medications are developed, new and more effective treatments arrive more quickly.

In fiscal year 2023, the Alzheimer’s Association continued its steadfast leadership in the fight against Alzheimer’s and all other dementia. Together with our passionate donors, volunteers, staff and advocates, we made tangible progress toward ensuring constituents who can benefit have access to the tools they need to be diagnosed and treated as well as ensuring quality care for those who are not eligible for the treatments currently available. And with your support, we will continue to fight tirelessly for a future where treatments, as well as the tools to one day prevent the disease itself, are accessible for everyone facing Alzheimer’s or another dementia — at any stage — in communities everywhere.

Our efforts and accomplishments in FY23 speak to the very core of our mission to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. We are proud to share some of our activities from this past year — a time of continued momentum — in this annual report.

We would be remiss if we didn’t acknowledge the contributions of former CEO Harry Johns, who ended 17 years of distinguished service to the Association in December 2022. Harry oversaw the Association’s growth into a powerful force that is now at the forefront of our movement. Due in large part to Harry’s guidance, the Association is committed to providing everyone impacted by the disease with resources and education to realize our vision of a world without Alzheimer’s and all other dementia. We cannot thank him enough for his tremendous leadership on behalf of the people we serve.

As we lead the Association, we remain grateful to those who make a difference in our mission and welcome those who joined the cause over the past year. Successes such as those highlighted in this report would not be possible without you.
**Report Overview**

The FY23 Annual Report details mission-related accomplishments within the six strategic objectives of the Alzheimer’s Association: providing and enhancing quality care and support; accelerating research; increasing concern and awareness; strengthening diversity, equity and inclusion; advancing public policy; and increasing revenue. These initiatives drive the Association’s efforts to end Alzheimer’s and all other dementia and offer help and hope to all those affected. Central to our work in all areas this fiscal year was ensuring equitable access to treatments.

**Providing and Enhancing Quality Care and Support**
Available via locations in communities across the country, our award-winning website, alz.org, and our 24/7 Helpline, the Association is instrumental in providing and enhancing care and support for all those affected by Alzheimer's and all other dementia through a commitment to reliable resources, support and information. In addition to working directly with families, we collaborate with health systems, long-term care and community-based services nationwide to facilitate solutions for delivering person-centered dementia care.

**Accelerating Research**
The world’s largest nonprofit funder of Alzheimer’s and dementia research, the Association is also the nonprofit with the highest impact in Alzheimer’s research worldwide as measured by InCites Clarivate™. In our role as the leading research convener, collaborator and coordinator, the Association is committed to accelerating global progress toward new methods of diagnosis, treatment, prevention and, ultimately, a cure. The Association committed a milestone $100 million in total annual research spending in FY23.

**Increasing Concern and Awareness**
The Association drives the nationwide discussion of Alzheimer’s and all other dementia and is the leader in the fight to end its devastation. By growing the conversation about the number of individuals affected by Alzheimer’s and its staggering economic and societal impact, the public and policymakers are enabled to take appropriate actions to change the course of the disease, and families can be empowered to raise their voices as they face its challenges.

**Strengthening Diversity, Equity and Inclusion**
The Association has long highlighted diversity, equity and inclusion as part of core values critically important to our work. We are committed to identifying and addressing barriers that may impede members of diverse communities from receiving Alzheimer’s education, care and support and to improving interventions and treatment for everyone.

**Advancing Public Policy**
As the leading voices for Alzheimer’s advocacy, the Association and the Alzheimer’s Impact Movement, a separately incorporated advocacy affiliate, successfully fight for critical research and care and support initiatives at the state and federal levels. (AIM also engages in certain political activities that the Association is prohibited from conducting, and those activities are not included in this report.) Together with our hundreds of thousands of advocates, we are relentless in our efforts to make Alzheimer’s a national priority while speaking up for the needs and rights of people living with the disease.

**Increasing Revenue**
Individuals, corporations and foundations further the Association’s mission through their dedicated involvement and support. From Walk to End Alzheimer’s® to fundraising galas to estate gifts and more, the Association deeply appreciates our many generous donors who demonstrate their powerful, ongoing commitment to ending Alzheimer’s through advancing research and enhancing the Association’s care and support efforts.
Providing and Enhancing Care and Support

*Delivering on its mission, the Alzheimer’s Association provided care and support more than 6.5 million times through channels including [alz.org](http://alz.org), care consultations, information and referrals, support groups, education programs and information. In this new era of treatment, the Association remains committed to ensuring people in every stage of the disease have access to resources that help them live well. Surveys indicate that constituents are highly satisfied with Association programs and services and would recommend them to others.*

The Association’s free national 24/7 Helpline (800.272.3900) is available around the clock, 365 days a year. Specialists and master’s-level clinicians received over 200,000 calls and online chats, offering confidential support and information to people living with dementia, caregivers, families and the public. The service is partially funded by a five-year, $6.2 million federal grant awarded by the Department of Health and Human Services Administration for Community Living.

The **Alzheimer’s Association National Early-Stage Advisory Group** comprises individuals living in the early stage of Alzheimer’s or another dementia who share their experiences through media outlets and other public channels to raise awareness, reduce stigma and provide guidance on the development of Association programs and services. Among other activities, they advocated for the Food and Drug Administration’s (FDA) approval of lecanemab, the first traditionally approved Alzheimer’s treatment that addresses the underlying biology of the disease, and called on the Centers for Medicare & Medicaid Services (CMS) to provide unrestricted coverage of all Alzheimer’s treatments approved by the FDA.

Committed to ensuring the highest quality of care for people living with dementia in all communities, the Association empowers professional care workers with educational resources. Nearly 3,000 professionals working in long-term and community-based care settings completed **essentiALZ® – Alzheimer’s Association Training and Certification**, an online program. The training educates professionals on how to apply evidence-based, person-centered care practices when providing care to people living with dementia. The Association received continuing education activity accreditation from Rush University in Chicago for the program. Learners who complete the essentiALZ training and certification can now claim credit for continuing nursing education (CNE), National Association of Long-Term Care Administrator Boards (NAB), and continuing education for social work, physical therapy, psychology, occupational therapy and nutrition, preparing to continue to improve the quality of care for those living with Alzheimer’s and other dementia.

To address the rapidly changing landscape in Alzheimer’s treatments, the Association updated its **New Advances in Alzheimer’s Treatments** education program to address FDA-approved anti-amyloid therapeutics. Participants learn about how this class of drugs is designed to work, who may be a candidate for treatment, potential benefits and side effects, availability and pathways for access, and Association resources.

The Association launched a Spanish online and in-person version and an English online version of its evidence-based education program **Managing Money: A Caregiver’s Guide to Finances**. The program teaches caregivers about the costs of caregiving and the benefits of early planning, avoiding financial abuse and fraud, starting a conversation about finances, and assessing financial and legal needs.

The Association launched its eighth nationwide **Project ECHO® (Extension for Community Healthcare Outcomes) Program**, along with two regional offerings, for primary care physicians. The program connects dementia care experts with primary care practices in a series of interactive, case-based telementoring sessions, enabling clinicians to better manage dementia, and emphasizes high-quality, person-centered care in community-based settings. Since its inception in 2018, more than 100 primary care practices and nearly 350 primary care physicians have completed ECHO training, influencing nearly 400,000 lives. Evaluations following programs delivered in FY23 showed statistically significant increases in participants’ confidence and knowledge.
The Alzheimer's Association Dementia Care Provider Roundtable brings together industry leaders from across the continuum of long-term and community-based care to discuss key areas in the delivery of quality person-centered care. The roundtable's 30 member organizations serve over 600,000 people daily in more than 5,300 points of service in all 50 states and 15 countries, and support approximately 400,000 staff. The roundtable awarded a research grant from the Association's Advancing Research on Care and Outcome Measurement (ARCOM) grant program, focused on improving the lives of individuals living with dementia and their care partners.

Through its health systems initiative, the Association engaged 400 health systems and payers nationwide to increase equitable access to care and the quality of dementia care. Health systems partner with the Association and commit to policy changes, with over 13 million people benefiting from these system changes in FY23.

The Alzheimer's Association Innovation Roundtable brings together innovators, champions and experts across the health care sector to reduce risk, improve early detection and increase access to evidence-based, person-centered care for those facing Alzheimer’s and all other dementia. In FY23, the group concluded its first year with an innovation challenge and pitch competition that identified innovations to increase cognitive assessment and early detection and diagnosis of dementia within primary care settings. Winners of the competition received funding for 1) clinically validated digital cognitive tests that measure and monitor the state of one’s cognition paired with a cognitive health program; 2) a solution that integrates brain biomarkers, cognitive assessment tools and virtual care solutions; and 3) a data-driven solution that combines objective olfactory testing with machine learning algorithms.

The Association introduced an enhanced version of ALZNavigator™, an interactive online tool that provides resources and creates customized action plans for individuals impacted by the disease. ALZNavigator also offers resources for LGBTQ+ individuals, veterans, those living with younger-onset Alzheimer’s and people who do not yet have a diagnosis. In the first three months following its relaunch, there were over 38,000 sessions conducted by nearly 31,000 users, almost all of whom were new to the platform.

The Association relaunched ALZConnected®, a free online community for people living with dementia and those who care for them, with new features to improve the user experience. Members can post questions about dementia-related issues, offer support, and create public and private groups around specific topics. Over 3,000 new members joined ALZConnected in the first three months after its relaunch, a more than 10% growth in membership.

Constituents engaged in more than 660,000 sessions using the Alzheimer’s Association & AARP Community Resource Finder, a growing database of dementia and aging-related resources. Community Resource Finder connects individuals living with dementia and their caregivers with local programs and services.

Nearly 16,000 people registered for ALZ Talks, the Association’s free monthly webinar series featuring friendly and insightful conversations on a variety of topics with people living with Alzheimer’s, caregivers and dementia experts. The series shares information and resources, while conveying that no one needs to face this disease alone. To date, ALZ Talks has received over 58,000 on-demand views through YouTube and nearly 760,000 views on Facebook.

The Association and the Centers for Disease Control and Prevention (CDC) released the fourth edition of The Healthy Brain Initiative: State and Local Road Map for Public Health, 2023-2027, which provides public health officials nationwide with a set of strategies to promote brain health and improve the quality of life for people living with dementia and their caregivers. The new edition includes 24 actions to promote brain health, improve diagnoses and maximize care, with a larger focus on partnerships and health equity.
Accelerating Research

The Association committed a milestone $100 million in total annual research spending, the largest allocation since the organization’s founding, including more than $74 million in grants for new scientific investigations. These grants represent proposals ranked highest by a three-tier peer-review process in a highly competitive field. As the world’s leading nonprofit funder of Alzheimer’s and dementia research, the Association is currently investing more than $360 million in over 1,000 active best-of-field projects in 53 countries, spanning six continents. The Association’s commitment to research is critical in the new era of treatment by advancing projects that drive us toward more effective therapies for all populations impacted by Alzheimer’s and other dementia.

The Association continues to drive the diversification of clinical trials through the Part the Cloud global research grant program. In FY23, Part the Cloud provided over $4.75 million to move forward five new high-risk, high-reward studies aimed at potential treatments. The continued success of Part the Cloud is due to the drive and vision of philanthropist and longtime Alzheimer’s Association champion Mikey Hoag; since Hoag founded Part the Cloud in 2012, the program has funded 65 studies that have generated more than $1.3 billion in follow-on funding.

The landmark Association-led U.S. POINTER study continues to work to better understand the relationship between lifestyle interventions and dementia risk. With recruitment complete, more than 2,000 people are enrolled via study sites in Chicago (Advocate Health Care, Rush University Medical Center), Houston (Baylor College of Medicine in collaboration with Kelsey Seybold Foundation), Providence, Rhode Island (Butler Hospital in collaboration with LifeSpan), Sacramento, California (UC Davis School of Medicine), and Winston-Salem, North Carolina (Wake Forest School of Medicine), and over 30% of participants are from historically underrepresented populations. The Association has invested over $45 million in U.S. POINTER, and the National Institute on Aging (NIA) has made four awards expected to total up to nearly $65 million for add-on studies, bringing the total amount invested to more than $110 million.

The Association supported recruitment and retention activities for the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS), a two-year observational study designed to understand the genetic, biological and clinical processes involved in younger-onset (or early-onset) Alzheimer’s disease — defined as when symptoms develop before age 65. The study currently follows 672 people at 18 U.S. sites. The Association launched a LEADS Diversity Recruitment Funding Program to support community-based recruitment efforts aimed at enrolling participants from historically underrepresented populations and a family meeting to support individuals and families by offering presentations, panel discussions and resources.

The Association has been a funder of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) since its advent in 2004 but took on a new role as convener of the Private Partner Scientific Board (PPSB) in FY23. The new ADNI grant will fund a five-year extension of the study, termed ADNI4. ADNI’s goal has been to validate biomarkers for Alzheimer’s disease clinical trials and in its several incarnations has had a major impact on Alzheimer’s research and clinical trials, yielding more than 4,500 scientific publications. There are currently 28 members of the ADNI4 PPSB, who provide needed insight and guidance to the ADNI investigators, fund research projects and participate in working groups that parallel key focus areas of ADNI.
The Association and the Fred A. and Barbara M. Erb Family Foundation announced the establishment of the Fred A. Erb Clinical Research Science Fellowships. These fellowships will support career advancement for 10 outstanding clinician scientists over the next five years to help expand and strengthen the field and move closer to effectively treating and preventing Alzheimer’s and all other dementia.

The Association continued to provide leadership and support for New IDEAS: Imaging Dementia — Evidence for Amyloid Scanning Study, alongside the American College of Radiology (ACR), the Centers for Medicare and Medicaid (CMS) and recruitment experts from Vanderbilt University and the University of North Carolina at Chapel Hill. This study is enrolling 7,000 Medicare beneficiaries of diverse racial and ethnic backgrounds — at least 4,000 of whom will be Black/African American or Latino/Hispanic-identifying — to receive amyloid PET brain imaging that can measure the buildup of abnormal amyloid protein in the brain, one of the key hallmarks of Alzheimer’s. The New IDEAS Biorepository, funded by the Association, will advance the science of blood-based tests for Alzheimer’s and all other dementia.

The Alzheimer’s Association International Conference® (AAIC®), the largest forum to advance dementia science, is where top researchers from across the globe meet to share discoveries and collaborate. Over 9,500 members of the dementia research community convened at AAIC 2022 in San Diego and online, including more than 4,500 in person. Groundbreaking research presented at AAIC 2022 included findings on the impact of structural, interpersonal and institutional racism on cognitive decline; a correlation between hypertensive disorders during pregnancy and increased risk of dementia; the impact of COVID-19 smell loss on long-lasting cognitive problems; a link between ultraprocessed foods and cognitive decline; and a variety of updates on advancements in treatments and clinical trials.

The Association continued to expand its global reach through a growing portfolio of scientific meetings. The NIA and the Association supported the 5th Annual NIA-AA Symposium on Enabling Precision Medicine for Alzheimer’s Disease Through Open Science as part of AAIC 2022 preconference offerings. Convening over 200 members of the research community, the meeting was a valuable opportunity to learn and share developments in precision medicine principles and open science practices.

The virtual AAIC Neuroscience Next showcased the work of neuroscience students, postdoctoral researchers and early career research professionals worldwide in a unique “hybrid hub” model. More than 2,600 registrants from 93 countries gathered online to learn from and support the next generation of researchers.

The AAIC Satellite Symposium brought together nearly 700 researchers from 54 countries in Mexico City and online to discuss research advances in public health, diagnosis and treatment within Latin America. Over 53% of attendees were based in low- and middle-income countries.

The Association convened the AAIC Advancements: APOE and AAIC Advancements: Immunity conferences, which assembled more than 850 scientists from 54 countries and 600 scientists from 46 countries, respectively. Attendees shared the latest research findings and ideas about the roles of APOE, a gene known to influence risk, and immunity in Alzheimer’s and all other dementia.

The Dementia and Brain Ageing in Low- and Middle-Income Countries symposium, made possible by an NIA grant, was hosted in collaboration with Newcastle University, University of Texas Rio Grande Valley, the Global Brain Health Institute (GBHI), the World Federation of Neurology’s Aphasia, Dementia and Cognitive Disorders Specialty Group, the International Brain Research Organization (IBRO), AgeCap Sweden and the African Dementia Consortium (AfDC) in Nairobi, Kenya. Over 330 individuals from 53 countries registered for the event, with 69% based in low- and middle-income countries.
The Association, the American College of Radiology, the American Society of Neuroradiology, the Department of Biostatistics, Brown University School of Public Health, the Critical Path Institute and the ALZ-NET Project Team, along with other clinical research experts, launched the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET). Led by the Association, which provided the initial funding, ALZ-NET is designed to collect routine clinical practice data from health care professionals caring for people living with Alzheimer’s who are taking an FDA-approved disease-modifying treatment, with a goal of quickly and transparently sharing data and outcomes. ALZ-NET has over 100 clinical sites in various stages of the startup process and is also aligning with international registry efforts across 11 other countries.

The Alzheimer’s Association Global Workgroup released consensus appropriate use recommendations for blood-based biomarkers (BBMs) in the clinic and in research trials. The workgroup also defined both short- and long-term research priorities needed to fill significant knowledge gaps that still exist, such as how well BBMs work in diverse communities and in those living with multiple health conditions.

The Association announced an investment of $10.85 million to the EQT Life Sciences’ LSP Dementia Fund, an international venture capital fund that invests in companies developing promising, high-impact treatments for Alzheimer’s and other neurodegenerative diseases. In another example of how the Association is accelerating innovation in dementia research, the commitment expands its funding into broader and varied areas of drug development to advance and diversify the research pipeline and available treatments for people living with Alzheimer’s or another dementia.

The Alzheimer’s Association Interdisciplinary Summer Research Institute provides an immersive, no-cost opportunity for early career researchers in psychosocial care and public health to launch a career in dementia science and accelerate breakthroughs. Throughout the five-day program in FY23, which featured faculty from the Association, attendees learned from experts through group sessions and individual mentoring.

TrialMatch® is the Association’s free service offering customized lists of clinical studies based on user-provided information. The TrialMatch database has over 370,000 users and includes more than 700 clinical trials, including international studies and locations. In FY23, TrialMatch had more than 27,000 sessions, over 4,200 web-based referrals and nearly 4,900 calls supporting over 700 studies, including New IDEAS and LEADS. A text-to-join feature was introduced to allow for greater accessibility to constituents.

The Alzheimer’s Association Research Roundtable engages scientists from the pharmaceutical, biotechnology, diagnostics, imaging and cognitive testing industries worldwide in a precompetitive platform to discuss key areas in Alzheimer’s science, with a mission of advancing the research, development and management of new treatments. The roundtable consisted of more than 20 member companies in FY23.

For the eighth year, the Alzheimer’s Association Business Consortium (AABC) continued to advance Alzheimer’s and dementia research through innovation by small, startup biotechnology, diagnostic and contract research organizations. The AABC works to achieve its goals by focusing on areas of common interest to advance the field as well as the goals of its more than 60 member companies.
The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) is an inclusive global network of over 10,000 scientists, clinicians and dementia professionals in more than 120 countries. In FY23, the percentage of members based in low- and middle-income countries rose from 11% to 20%, and the number of professional interest areas (PIAs) — subgroups of researchers who share common scientific interests — grew to 30. PIAs engaged with their members through 154 webinars and networking sessions, which received over 8,500 live views; published 16 journal articles, including seven in the Alzheimer’s & Dementia® journal family; and contributed 21 featured research sessions to AAIC 2022. In addition, the ISTAART Ambassador program continued to build awareness of ISTAART activities, delivering the “Introduction to ISTAART” presentation more than 40 times to over 1,600 scientists, clinicians and dementia professionals worldwide.

Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association is the leading peer-reviewed monthly scientific journal in Alzheimer’s and dementia. The publication’s 2023 impact factor, a measure of how many times another researcher references a publication’s articles and therefore its influence in the scientific community, led this flagship publication to be the top-ranked disease-specific journal in clinical neurology and fourth overall. Two open-access sister journals — Diagnosis, Assessment and Disease Monitoring (DADM) and Translational Research & Clinical Interventions (TRCI) — also saw continued growth in influence.

Funded by the Association, GAAIN is the first online platform to provide free, instant access to data normally restricted to a handful of Alzheimer’s researchers, uniting a diverse and geographically distributed network of partners to foster discovery, collaboration and sharing. With more than 36,000 unique data attributes linking together over 60 research studies with over 575,000 participants, GAAIN serves as a one-of-a-kind resource for the global Alzheimer’s and dementia community.
Increasing Concern and Awareness

The 2023 edition of *Alzheimer’s Disease Facts and Figures* — the Association’s annual compilation of statistics and information detailing the impact of Alzheimer’s and dementia on individuals, families, government and the nation’s health care system — found that the national cost of caring for individuals living with Alzheimer’s or other dementias will be $345 billion in 2023, a $24 billion increase from a year ago. The accompanying special report, *The Patient Journey In an Era of New Treatments*, offered new insights on why too often individuals living with memory concerns and their doctors are not discussing the disease, missing a critical first step toward diagnosis and potential treatment.

The Association centered efforts on the FDA’s accelerated approval of lecanemab (Leqembi®) and urging the Centers for Medicare & Medicaid Services (CMS) to change its policy preventing individuals living with early Alzheimer’s from accessing treatments, which included an advertising campaign consisting of digital displays, newsletter sponsorships, targeted print placements and social media. The campaign garnered more than 100 million impressions and over 25,000 petition signatures.

Each June, the Association recognizes Alzheimer’s & Brain Awareness Month as an opportunity to hold a global conversation about the brain and Alzheimer’s and all other dementia. In FY23, the Association conducted rallies in all 50 states to urge CMS to change its treatment coverage policy. The Association also invited people across the world to participate in The Longest Day® fundraiser to fight the darkness of Alzheimer’s through an activity of their choice.

The Association’s website, alz.org, continued to serve as a valuable resource on Alzheimer’s care, support and research, providing services to constituents nearly 20 million times. The Association also delivered critical Alzheimer’s information to the public through 6.6 billion total media impressions in traditional and nontraditional forms, including blogs, social media, and paid and earned placements nationally and locally.

Social media continued to drive conversation about Alzheimer’s and all other dementia and the Association. The combined social media following on Facebook, Instagram, TikTok, YouTube and X (formerly Twitter) increased by 9% to more than 1.4 million users. Engagement on our posts significantly outperformed nonprofit benchmarks, evidencing the Alzheimer’s community’s continued interest in staying up to date on Association news and willingness to publicly share information about the cause.

In partnership with the Ad Council and NASCAR, the Association launched new public service announcements (PSAs) featuring NASCAR driver Ryan Blaney sharing his family’s journey with Alzheimer’s following his grandfather Lou’s diagnosis. The PSAs encouraged families to have a conversation with loved ones when they notice changes in cognition or behavior, and stressed the benefits of early detection, including access to treatment options, an opportunity to participate in clinical trials and more time to plan for the future. The Ryan Blaney Family Foundation led a $50,000 Match Challenge that culminated in a check presentation by Blaney at the inaugural 2023 NASCAR Cup Series Chicago Street Race.

Ryan Blaney
A new Walk to End Alzheimer’s marketing campaign, “This Is Why We Walk,” focused on the many reasons people take part in the event, the world’s largest fundraiser for Alzheimer’s care, support and research. The messaging spanned TV, radio, print, digital and social media and alluded to care, support and research, highlighting how Walk supports the Association’s full mission, and reflected the current state of treatment and our efforts to ensure access.

Four-time Grammy-nominated country artist Mickey Guyton joined the Association’s digital storytelling series Music Moments to raise awareness during Alzheimer’s & Brain Awareness Month. Guyton performed a heartfelt rendition of her song “How You Love Someone,” coupled with an intimate behind-the-scenes interview sharing her personal connection to the cause through her grandmother.

In recognition of National Alzheimer’s Disease Awareness Month and National Family Caregivers Month, the Association partnered with the Golf Channel to produce a month-long series to educate viewers about Alzheimer’s and Association resources. Topics included the importance of early detection and diagnosis, warning signs and the benefits of early diagnosis; the challenges families face following an Alzheimer’s diagnosis; and research advances and the important leadership role the Association is playing in the fight against the disease.

Teams across Major League Baseball, including the Boston Red Sox, Chicago Cubs, Chicago White Sox, Milwaukee Brewers, New York Yankees, Oakland Athletics, San Diego Padres, San Francisco Giants and Seattle Mariners, took part in Alzheimer’s Association Awareness Games by featuring opportunities for fans to learn about Association efforts to end the disease and donating tickets to Association constituents. Teams also participated in initiatives such as the Major League Memories alumni player engagement program at senior care facilities.

For the 14th year in a row, the Association achieved top-three status in large nonprofits in The NonProfit Times’ annual “Best Large Nonprofits to Work For” survey, securing the #2 ranking in FY23. The annual survey emphasizes employee development, recognition measures and workplace culture.
Strengthening Diversity, Equity and Inclusion

Engaging diverse perspectives is critical to achieving health equity — meaning that all communities have a fair and just opportunity for early diagnosis of Alzheimer’s or another dementia and access to risk reduction, quality care and treatments. The Association continued making strides in FY23 in expanding its reach and responding with resources to address the disproportionate impact of Alzheimer’s and all other dementia on underrepresented communities.

The Association’s inaugural Diversity, Equity and Inclusion Report documented its ongoing work in pursuit of health equity in dementia care. The report highlighted important progress the Association is making in advancing diversity, equity and inclusion initiatives across all areas of its mission nationwide.

A new partnership between the Association and 100 Black Men of America, Inc. (The 100), will promote brain health and increasing awareness of care and support resources for Black Americans living with Alzheimer’s or another dementia and their caregivers. The groups will collectively advance The 100’s health and wellness goals to raise awareness, provide access to health care and offer information that will ultimately promote behavior changes resulting in a healthier lifestyle.

The Association and The Links, Incorporated, announced a partnership to provide Alzheimer’s information and resources to Black American communities. Each entity will raise awareness and maximize support for individuals and families impacted by Alzheimer’s or another dementia while engaging in meaningful discussions to address health equity and health disparities as they relate to dementia care.

Other new FY23 partnerships included the Association for Clinical and Translational Science, the Asian & Pacific Islander American Health Forum, the National Minority Health Association, the Nurses on Boards Coalition and the Philippine Nurses Association. The Association also renewed its partnership with SAGE (Services and Advocacy for LGBTQ+ Elders) to continue to provide dementia information and resources to LGBTQ+ communities.

Association representatives attended the 46th Annual Conference of the National Black Caucus of State Legislators (NBCSL), a new national diversity, equity and inclusion partner. The collaboration with NBCSL will focus on increasing participation in clinical trials; advancing early detection and diagnosis of Alzheimer’s and all other dementia; and developing and implementing state Alzheimer’s plans.

The Association and Gdavis Productions and Films, LLC, brought “Unforgettable,” a dynamic and emotional stage play that showcases the effects of caring for a loved one living with Alzheimer’s in
an easy-to-understand and relatable way, to NBCSL’s 46th Annual Legislative Conference and at-capacity performances in Dallas and Atlanta. “Unforgettable” sheds light on the importance of early detection, recognizing the early warning signs of Alzheimer’s and the importance of underrepresented communities’ participation in clinical trials.

The Association and the African Methodist Episcopal Church (AME) hosted the third annual Connectional Purple Sunday, which raises awareness of Alzheimer’s disease among the Black American community. Rep. Maxine Waters (D-Calif) participated to discuss the benefits of collaborative work between the Association and AME in her district. Attendees learned about the impact of Alzheimer’s in their community, how to recognize the signs, the importance of early detection, and how to access Association care and support resources.

The Association joined leading brain health and dementia researchers and community leaders for the second annual Black Men’s Brain Health Conference. The conference examined how various risk factors contribute to Black men’s higher risk for Alzheimer’s and all other dementia and explored how the brain’s ability to adapt to significant sources of stress affects their cognitive health.

Latinos are the largest minoritized racial/ethnic group in the United States but also comprise a small, unrepresentative fraction of clinical trial participants. Leaders in health equity issued an urgent call to address the underrepresentation of Latinos in Alzheimer’s and dementia clinical trials in an article, co-authored by Carl V. Hill, Ph.D., MPH, Association chief diversity, equity and inclusion officer, and Yarissa Reyes, director, Diversity, Equity and Inclusion, in the Association journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions.

The Association’s free ALZ Talks webinars provide education, information, news and resources on a variety of dementia and caregiving topics. The first Spanish-language ALZ Talks took place in October 2022, with a second edition taking place in June 2023.
Advancing Public Policy

The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM), a separately incorporated advocacy affiliate, worked independently and together to the extent allowed by law to continue to advance critical federal and state policy priorities in FY23. In collaboration with their respective dedicated networks of passionate advocates, the Association and AIM achieved numerous successes on Capitol Hill and at the state and local levels.

The Association and AIM were instrumental in the passage of the federal FY23 budget that included a $226 million increase for Alzheimer’s and dementia research funding at the National Institutes of Health (NIH) and $33 million to implement the BOLD Infrastructure for Alzheimer’s Act. The total annual federal investment in Alzheimer’s and dementia research is now more than $3.7 billion.

The budget legislation included key provisions of the bipartisan Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act and language to strengthen the Food and Drug Administration’s (FDA) accelerated approval pathway. The ENACT Act would expand education and outreach to underserved populations, encouraging the diversity of clinical trial staff and reducing the burden of participation. Strengthening the accelerated pathway will allow people living with an unmet medical need like Alzheimer’s or another dementia to gain earlier access to new and innovative treatments.

The Association continued to urge the Centers for Medicare & Medicaid Services (CMS) to reverse its Alzheimer’s treatment coverage policy, which prevented those living with early Alzheimer’s from accessing treatments traditionally approved by the FDA. The Association filed a formal request asking CMS to provide full and unrestricted coverage. As part of efforts at convincing CMS to change its policy, the Association conducted rallies in all 50 states. CMS adjusted its policy in July 2023 to provide access but only to people enrolled in the FDA’s patient registry; the Association believes that a registry as a condition of coverage is an unnecessary barrier.

Working with bipartisan congressional champions, the Association and AIM drove the passage of the NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act by the Senate Committee on Health, Education, Labor and Pensions (HELP). The NAPA Reauthorization Act would extend the National Alzheimer’s Project Act, a landmark piece of legislation that fundamentally changed the way our nation addresses Alzheimer’s and all other dementia.
The Alzheimer’s Accountability and Investment Act aims to ensure Congress continues to hear directly from scientists at NIH what resources are necessary to prevent and effectively treat Alzheimer’s disease; in FY23, NIH released its annual professional judgment budget for Alzheimer’s and dementia research, requesting an additional $321 million in funding for fiscal year 2024.

The House and Senate reintroduced the bipartisan Comprehensive Care for Alzheimer’s Act, asking the Center for Medicare & Medicaid Innovation (CMMI) to test a different payment structure for dementia care management that would improve the quality of care, ease the challenges of caregiving and reduce costs.

As part of the 2023 Alzheimer’s Impact Movement Advocacy Forum, the first-ever Rally for Access was held outside the White House, where purple-clad advocates gathered to fight for the reversal of the original CMS policy. On Hill Day, advocates met with elected officials to encourage their support for critical legislation and increased federal Alzheimer’s and dementia research funding in addition to changing the CMS policy.

At the National Alzheimer’s Dinner, Sens. Susan Collins (D-Maine) and Amy Klobuchar (D-Minn.) received the AIM Humanitarian Award. The senators were honored for their significant policy contributions to the fight against Alzheimer’s and all other dementia.

Advocates used digital platforms to make over 115,000 connections with lawmakers regarding public policy issues, including nearly 92,000 emails and over 23,000 tweets. More than 400 personalized videos were shared with elected officials.

The Association held more than 400 events with members of Congress, including virtual meetings, virtual town halls, Coffees with Congress and conversations at Walk to End Alzheimer’s. Advocates also submitted nearly 800 letters to the editor, with approximately 53% published in media outlets nationwide.

The Association hosted the inaugural State Dementia Services Coordinator (DSC) Summit in Washington, D.C., continuing its work with state policymakers to improve the lives of those impacted by Alzheimer’s and all other dementia. The event convened state agency officials from 26 states and the District of Columbia to collaborate, share their experiences and discuss solutions to help the more than 6 million Americans living with Alzheimer’s and their families.

Several priority bills in alignment with the Association’s coordinated nationwide state policy priorities were signed into law following active engagement by Association and AIM staff and advocates. These included legislation to increase access to care, support and treatment; improve quality of care; advancing risk reduction, early detection and diagnosis; and ensure a coordinated statewide response to the Alzheimer’s crisis.
Increasing Revenue

Generous support from constituents, corporations and organizations help make a difference in the lives of those facing Alzheimer’s and all other dementia while moving us closer to ending the disease. Association donor and partner contributions totaled more than $374 million in FY23.

Strategic direct marketing efforts using print and digital campaigns raised over $76.1 million and engaged more than 660,000 donors. More than $7.5 million was raised on Facebook and Instagram through birthday and evergreen fundraisers, and signature event fundraisers contributed an additional $6.7 million. Alternative giving opportunities through Facebook Challenges raised more than $600,000.

**Walk to End Alzheimer’s**, the world’s largest event to raise awareness and funds for Alzheimer’s care, support and research, engaged over 300,000 participants and raised $89.5 million — a 5% increase from FY22. Thanks to tireless support from communities across the country, Walk to End Alzheimer’s retained its second-place standing in the Peer-to-Peer Forum’s Top 30 rankings for all fundraising runs, walks and cycling events nationwide. Fifty-nine National Teams raised more than $13 million combined.

**The Longest Day** had a record-breaking year, raising $12 million, including $2.8 million from 21 Global Teams. Thousands of people across the world participated in activities such as arts and crafts, baking and cooking, hiking, bridge, working out, golf and pickleball to raise funds and awareness to end Alzheimer’s. Year-round participant engagement efforts contributed to increased revenue through fundraisers and donations.

**Ride to End ALZ®**, the Association’s signature cycling event that directly raises funds for Alzheimer’s research, grew by over 50%, with five in-person rides and three opportunities to ride in a location of the participants’ choosing. Nearly 3,000 individuals representing all 50 states and 10 countries raised a record $4.2 million.

Revenue from generous corporate contributors totaled more than $21.4 million and earned millions of impressions to increase concern and awareness of Alzheimer’s and all other dementia. A complete list of corporate supporters at the $50,000 level and above is available later in this report.

Financial services firm **Edward Jones continued its strategic alliance with the Association**, giving more than $4.5 million through corporate contributions and Walk to End Alzheimer’s teams. Since 2016, the firm and its associates have raised more than $40 million to help end Alzheimer’s, and have committed $50 million to the Association by 2025. The company supported Walk to End Alzheimer’s as a National Presenting Sponsor, along with 12,700 participants on over 3,100 teams who raised nearly $3.6 million. Demonstrating its commitment to research, Edward Jones served as a sponsor of the Alzheimer’s Association International Conference 2022 (AAIC) through a $50,000 gift and provided a yearly corporate contribution of $900,000 to
support Alzheimer’s research in the lab, clinic and community, with the majority of funding supporting the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Primary Prevention Trial.

**CNO Financial and Bankers Life** hosted its 21st annual Forget Me Not Days® fundraiser for The Longest Day. A contribution of more than $400,000 in support of the Association was made through corporate, public and associate donations. As a Walk to End Alzheimer’s National Team, CNO’s participation included fundraising and sponsorship of events across all six of its corporate locations. Since 2003, this partnership has raised nearly $7.5 million for the Association.

In its second year partnering with the Association, **Cutco Cutlery** offered an expanded selection of limited-edition purple products and donated 10% of sales during Alzheimer’s & Brain Awareness Month. The dedication of clients and associates to fighting Alzheimer’s resulted in record-breaking sales, raising over $300,000. Cutco also helped increase awareness of the disease by sharing the 10 Warning Signs of Alzheimer’s with customers.

**BJ’s Restaurants, Inc.** served as a Proud Supporter of The Longest Day for a fifth year. Guests who dined in or ordered takeout throughout Alzheimer’s & Brain Awareness Month were invited to donate to the Association, raising a record-breaking $272,000. BJ’s Restaurants and its guests have raised more than $1 million for Alzheimer’s care, support and research.

Continued support from the Association’s pharmaceutical, biotech and life science sponsors and participants helped advance critical scientific initiatives, including AAIC 2022, the Alzheimer’s Association Research Roundtable (AARR), the Alzheimer’s Disease Neuroimaging Initiative Private Partner Scientific Board (ADNI-PPSB) and the Alzheimer’s Association Innovation Roundtable (AAIR).

**Part the Cloud**, founded in 2012 by philanthropist Mikey Hoag in partnership with the Association, continues to fuel scientific advancements. Over 10 years, Part the Cloud has raised $68 million to fuel 65 research projects that have gone on to receive more than $1.3 billion in follow-on funding. The Part the Cloud Luncheon, held in Menlo Park, California, raised nearly $1 million to advance high-risk, high-reward research projects aimed at potential new treatments and devices for Alzheimer’s and all other dementia. Part the Cloud was named a Best Health Fundraising Event in the 2nd Annual Anthem Awards in recognition of its efforts to fund Alzheimer’s research with the highest probability of slowing, stopping or ultimately curing the disease.

The **Jerome H. Stone Philanthropy Award for Alzheimer’s Research** recognizes the world’s top philanthropists for advancing dementia science through their generous and transformative financial commitments. The Association presented the FY23 award to **Vicky Patel**, who made a leadership gift to support the Association’s research program in 2015 and has sponsored multiple research grants, including U.S. POINTER.

Comprising philanthropists who make a commitment of $1 million or more to the Association, the **Zenith Society** sets the bar for philanthropic leadership, engagement and impact. The Society welcomed three new members, increasing membership to 102. The Association received 10 Zenith-level gifts from members in FY23, including gifts to support research from the Fred A. and Barbara M. Erb Family Foundation, Mikey and Jay Hoag, JTMF Foundation, National Active and Retired Federal Employees Association (NARFE) and Eddie and Jo Allison Smith Family Foundation. The Erb Foundation’s gift established the Fred A. Erb Clinical Research Fellowship. Other Zenith gifts were received from the Ray and Dagmar Dolby Family Fund, to support an effort to increase engagement in medical research among disproportionately burdened populations; Judy and Michael Harrington, to support the Association’s diversity, equity and inclusion work in Indiana; and Sharon and Al Mulvey, to support dementia care coordination in New England. Zenith Society members generated a total of $52 million for the Association through personal gifts, special events, direct marketing challenges, Walk to End Alzheimer’s and more.

The **Aspire Society** recognizes individuals and foundations who give $10,000 or more per year through outright gifts, galas, Walk to End Alzheimer’s and other avenues to support every pillar of the Association’s mission. The Association was honored to acknowledge 1,600 Aspire Society members in FY23.
The **Founders Society** honors those extraordinary people who make future gift commitments to the Association through their estate plans. The Association welcomed 216 new Founders Society members, bringing total membership to more than 2,500. The Association received $68 million as a beneficiary of wills, trusts, charitable gift annuities and other planned gift arrangements.

The **Alois Society**, which includes donors who make an annual gift of $1,000 to $9,999, raised $20.9 million to help fuel and guide the Association’s efforts.

The **Alzheimer’s Association Imagine Benefit**, built on the legacy of the Rita Hayworth Gala, raised nearly $800,000. Founded by Princess Yasmin Aga Khan, the event was held at the iconic Jazz at Lincoln Center in New York City, and highlights included performances from Aaron Diehl, Lisa Fischer, Scarlet Envy, Talia Suskauer and the Harlem Gospel Choir.

The **Chicago Rita Hayworth Gala**, also founded by Princess Yasmin Aga Khan, was held at the Four Seasons Chicago and raised nearly $700,000. Kerry Peck, a former Illinois Chapter board member, and his law firm Peck Ritchey, LLC, received the 2023 Philanthropy Award.

Siblings Kimberly Williams-Paisley, Ashley Williams and Jay Williams hosted the fifth annual **Dance Party to End ALZ** in Nashville. Apple Music’s Beats 1 “Today’s Country” radio host Kelleigh Bannen emceed the lively event, which raised $535,000 for the Association’s research grant program.
Treasurer’s Report

The financial health of the Alzheimer’s Association was strong in FY23, with the organization’s Consolidated Statement of Financial Position reflecting total assets of more than $513 million as of the fiscal year ended June 30, 2023. Total revenues were more than $432 million, with over $374 million from donor contributions.

Expenses were well managed. Of the total consolidated expenses of $474 million, the Association expended $371 million on programmatic activities. The Association continues to meet and exceed minimum standards of 65% program expenses set by the BBB Wise Giving Alliance, devoting 78% of expenses to programmatic activities.

Continuing to make significant progress in the fight to end Alzheimer’s in FY23, the Association made its largest-ever total annual research investment: a milestone $100 million in total annual research spending, including more than $74 million in grants for new scientific investigations. As the world’s leading nonprofit funder of Alzheimer’s and dementia research, the Association is currently investing over $360 million in more than 1,000 active best-of-field projects in 53 countries.

Among other achievements, we provided care and support more than 6.5 million times through channels including alz.org, our 24/7 Helpline, support groups and education programs, and furthered our commitment to engaging underrepresented and underserved communities by providing resources to address the disproportionate impact of Alzheimer’s and all other dementia on these constituents. In large part due to the relentless efforts of the Association and the Alzheimer’s Impact Movement, a separately incorporated advocacy affiliate, a $226 million increase in federal Alzheimer’s and dementia funding was approved, bringing the total current federal research investment to over $3.7 billion.

We remain honored and grateful to our donors for respecting our stewardship, embracing our mission and continuing to serve as a vital part of our efforts to achieve our vision of a world without Alzheimer’s and all other dementia.

Bruce Baude
FY23 Treasurer, Board of Directors
Alzheimer’s Disease and Related Disorders Association, Inc.
Consolidated Statement of Financial Position
Year ended June 30, 2023
(In thousands)

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$33,805</td>
<td>$34,572</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>70,014</td>
<td>65,767</td>
</tr>
<tr>
<td>Other receivables</td>
<td>9,127</td>
<td>7,215</td>
</tr>
<tr>
<td>Inventories of education materials, at cost</td>
<td>1,140</td>
<td>994</td>
</tr>
<tr>
<td>Investments</td>
<td>293,712</td>
<td>318,371</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>6,890</td>
<td>7,894</td>
</tr>
<tr>
<td>Assets held in trust</td>
<td>46</td>
<td>290</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>22,544</td>
<td>23,048</td>
</tr>
<tr>
<td>Right-of-use operating assets</td>
<td>40,680</td>
<td>-</td>
</tr>
<tr>
<td>Beneficial interest in split-interest agreements</td>
<td>6,432</td>
<td>7,035</td>
</tr>
<tr>
<td>Beneficial interest in perpetual trusts</td>
<td>28,567</td>
<td>27,908</td>
</tr>
<tr>
<td>Other assets</td>
<td>770</td>
<td>791</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$513,727</strong></td>
<td><strong>$493,885</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$9,222</td>
<td>$12,838</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>119,715</td>
<td>113,364</td>
</tr>
<tr>
<td>Deferred compensation payable</td>
<td>822</td>
<td>1,046</td>
</tr>
<tr>
<td>Accrued expenses and other liabilities</td>
<td>29,270</td>
<td>27,226</td>
</tr>
<tr>
<td>Self-insurance reserve</td>
<td>1,469</td>
<td>1,713</td>
</tr>
<tr>
<td>Gift annuity obligations</td>
<td>5,897</td>
<td>5,473</td>
</tr>
<tr>
<td>Contract liability</td>
<td>5,329</td>
<td>3,138</td>
</tr>
<tr>
<td>Operating lease obligations</td>
<td>48,247</td>
<td>-</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>-</td>
<td>8,355</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td><strong>219,971</strong></td>
<td><strong>173,153</strong></td>
</tr>
</tbody>
</table>

| **NET ASSETS**                |          |          |
| Without donor restrictions    | 145,884  | 183,558  |
| With donor restrictions       | 147,872  | 137,174  |
| **TOTAL NET ASSETS**          | **293,756** | **320,732** |

| **TOTAL LIABILITIES AND NET ASSETS** | **$513,727** | **$493,885** |

These financial statements have been prepared by management in conformity with generally accepted accounting principles and include all adjustments which, in the opinion of management, are necessary to reflect a fair presentation. This presentation represents a summarization from audited financial statements.
Alzheimer’s Disease and Related Disorders Association, Inc.
Consolidated Statement of Activities
Year ended June 30, 2023
(In thousands)

<table>
<thead>
<tr>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVENUES, GAINS AND OTHER SUPPORT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and other financial assets</td>
<td>$324,411</td>
<td>$79,575</td>
</tr>
<tr>
<td>Non-financial assets</td>
<td>11,082</td>
<td>0</td>
</tr>
<tr>
<td>Conference registration and other</td>
<td>9,516</td>
<td>0</td>
</tr>
<tr>
<td>Dividends and interest, net of investment-related expenses</td>
<td>7,512</td>
<td>1,300</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>69,180</td>
<td>(69,180)</td>
</tr>
<tr>
<td>TOTAL REVENUES, GAINS AND OTHER SUPPORT</td>
<td>421,701</td>
<td>11,695</td>
</tr>
</tbody>
</table>

| EXPENSES |
|-----------------------------|-------------------------|-------|
| PROGRAM SERVICES |                         |       |
| Care, support and risk reduction | 118,483 | 0     | 118,483 |
| Research             | 100,125                 | 0     | 100,125 |
| Concern and awareness | 111,973 | 0     | 111,973 |
| Diversity equity and inclusion | 9,469 | 0     | 9,469   |
| Public policy         | 28,413                  | 0     | 28,413  |
| Mission engagement    | 2,411                   | 0     | 2,411   |
| TOTAL PROGRAM SERVICES | 370,874 | 0     | 370,874 |

| SUPPORTING SERVICES |                         |       |
| Fundraising         | 84,051                  | 0     | 84,051  |
| Management and general | 18,744 | 0     | 18,744  |
| TOTAL SUPPORTING SERVICES | 102,795 | 0 | 102,795 |

| TOTAL EXPENSES |                          |       |
| (DEFICIENCY) EXCESS FROM OPERATIONS | (51,968) | 11,695 | (40,273) |

| OTHER CHANGES IN NET ASSETS |                         |       |
| Net realized and unrealized gained (losses) in value of investments | 15,323 | (804) | 14,519 |
| Change in value of split-interest agreements | (255) | (762) | (1,017) |
| Change in value of perpetual trusts | 67 | 569 | 636 |
| Bad debt expense | (841) | 0 | (841) |
| TOTAL OTHER CHANGES IN NET ASSETS | 14,294 | (997) | 13,297 |

| CHANGE IN NET ASSETS |                          |       |
| (37,674) | 10,698 | (26,976) |

| NET ASSETS AT BEGINNING OF YEAR |                          |       |
| 183,558 | 137,174 | 320,732 |

| NET ASSETS AT END OF YEAR |                          |       |
| $145,884 | $147,872 | $293,756 |

These financial statements have been prepared by management in conformity with generally accepted accounting principles and include all adjustments which, in the opinion of management, are necessary to reflect a fair presentation. This presentation represents a summarization from audited financial statements.
Corporate Supporters

Annually, the generosity of corporate supporters and their employees helps the Alzheimer's Association to advance vital research and provide educational programming, care and support. We greatly appreciate their continuing contributions to our mission.

$1,000,000+
Edward Jones
Marshalls/TJX Foundation

$500,000 – $999,999
AmazonSmile
Eli Lilly & Company
Eisai

$250,000 – $499,999
Biogen
BJ’s Restaurant & Brewhouse
CARS
CNO Financial Group
Genentech
Google
Microsoft
Novo Nordisk
Rolex Watch USA

$100,000 – $249,999
Abbott Laboratories
AbbVie
American Senior Communities
Bank of America
Bundy Baking Solutions
Dot Foods
H-E-B
IBM
Johnson & Johnson
Liberty Mutual
Merck
OnStar
Procter & Gamble
Prothena Biosciences
Senior Star
Sentara Healthcare
Takeda
UnitedHealth Group

$50,000 – $99,000
Acumen Pharmaceuticals
Alector
Alzheon
Ameriprise
Apple
Athira Pharma
AT&T
Boeing
Bracket Global LLC
Cerveau Technologies
Chevron
Cogstate
Dell
Dignity Health
Elevance Health
Emerson Electric
Enigma Biomedical Group
Enterprise
Exelon
FedEx
GE HealthCare
Grandeur Peak Global Advisors
Intuitive Surgical
Jack Daniel’s Distillery
Novartis
Paragon Industries
PhRMA
PwC
Quest Diagnostics
RetireMed IQ
Round Pond Estate
Theisen Supply Inc.
US Foods
Vaccinex Inc.
Volta Oil Company
WCG Clinical
Wells Fargo
**Walk to End Alzheimer’s National Teams**

**The Longest Day Global Teams**

Walk to End Alzheimer’s National Teams and The Longest Day Global Teams are committed to raising critical funds and awareness for Alzheimer’s care, support and research. Below, we recognize these leading fundraising teams and thank them for joining the Alzheimer’s Association in our fight to end Alzheimer’s and all other dementia.

<table>
<thead>
<tr>
<th>$3,000,000+</th>
<th>Edward Jones</th>
</tr>
</thead>
</table>
| $1,000,000+ | American Contract Bridge League  
Brookdale Senior Living  
Sigma Kappa |
| $500,000 – $999,999 | American Senior Housing Association  
Life Care Services  
Senior Star |
| $250,000 – $499,999 | Alzheimer’s/Dementia Rotary Action Group  
Home Instead  
UnitedHealth Group  
Visiting Angels |
| $100,000 – $249,999 | Alpha Delta Kappa  
Always Best Care Senior Services  
Bankers Life  
Brightview Senior Living  
Cisco  
Dot Foods  
Erickson Senior Living  
Frontier Management  
Genesis Healthcare  
Integrated Financial Group  
KPMG  
LifeSpace Communities  
National Healthcare Corporation  
Parrot Heads in Paradise, Inc.  
Prager Metis  
ProMedica Senior Care  
Senior Living Communities  
Sinceri Senior Living  
Sunrise Senior Living  
The Judy Fund |
Board of Directors
Members of the Alzheimer’s Association Board of Directors volunteer to serve multiyear terms. They generously support our efforts with their time, talent and passion.

**Chair**
Sarah Lorance

**Vice Chair**
Minoo Javanmardian, Ph.D.

**Secretary**
Debra Pierson

**Treasurer**
Bruce Baude

**Executive Committee**
Dean Brenner
Geoff Heredia
Karyne Jones
Bruce Lamb, Ph.D.
Alex Tsao, Ph.D.
Julia Wallace
George Walz

**Directors**
Joe Arciniega
Andrew Dahlkemper
Gabriel de la Rosa
Wendy Drummond
David Gonzales
Tony Gonzales
Dozene Guishard, Ed.D.
David Hunter
Eileen Kamerick
Mikaela Louie
Joseph Montminy
Ryan Mundy
Donald Plaus
Elizabeth Shih
Irene Sudac
William Thomas
Derek van Amerongen, M.D.
Nicole Walker
Nancy Westcott

Medical and Scientific Advisory Group

**Chair**
Bruce T. Lamb, Ph.D.

**Members**
Karen Bell, M.D.
Lea Grinberg, M.D., Ph.D.
Oscar Lopez, M.D.
Mary Sano, Ph.D.
Malú Tansey, Ph.D.
Christopher van Dyck, M.D.

Alzheimer’s Association Research Staff
Maria C. Carrillo, Ph.D.
Rebecca M. Edelmayer, Ph.D.
Percy Griffin, Ph.D.
Claire Sexton, DPhil
Heather M. Snyder, Ph.D.
Christopher Weber, Ph.D.
Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Our vision is a world without Alzheimer’s and all other dementia.

800.272.3900 | alz.org